|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Polymeric black tea polyphenols inhibit 1,2-dimethylhydrazine induced colorectal carcinogenesis by inhibiting cell proliferation via Wnt/β-catenin pathway显示文摘 | Rachana Patel Arvind Ingle Girish B. Maru | 2007 | Toxicology and Applied Pharmacology2007，，1： | 2 |
| 2 | New Opportunities for the Drilling Industry Through Innovative Emulsifier Chemistry显示文摘 | Arvind Patel Syed Ali | | SPE0，，： | 1 |
| 3 | Study of nonaudit services, low balling, audit tenure, and auditor type: New Zealand and australian Evi- dence 显示文摘 | Patel Arvind Prasad | 2010 | Journal of Asia-Pacific Business2010，11，2： | 1 |
| 4 | Prediction of mechanicalproperties of compacted binary mixtures containing high - dose poorlycompressible drug显示文摘 | Sarsvatkumar Patel Arvind Kumar Bansal | 2011 | International Journal of Pharmaceutics2011，403，12： | 1 |
| 5 | Viral genotype correlates with distinct liver gene transcription signatures in chronic hepatitis C virus infection显示文摘 | Mark W. Robinson Elihu Aranday‐Cortes Derek Gatherer Rachael Swann Jolanda M. P. Liefhebber Ana Da Silva Filipe Alex Sigruener Stephen T. Barclay Peter R. Mills Arvind H. Patel John McLauchlan | 2015 | Liver Int2015，，10： | 1 |
| 6 | Characterisation of bacterially expressed structural protein E2 of hepatitis C virus显示文摘 | Maria S Yurkova Arvind H Patel Alexey N Fedorov | 2004 | Protein Expression and Purification2004，37，： | 1 |
| 7 | Synthesis and anticancer evaluation of novel 2-cyclopropylimidazo[2,1- b ][1,3,4]-thiadiazole derivatives显示文摘 | Malleshappa N. Noolvi Harun M. Patel Navjot Singh Andanappa K. Gadad Swaranjit Singh Cameotra Arvind Badiger | 2011 | European Journal of Medicinal Chemistry2011，，9： | 1 |
| 8 | Dual purpose reversible reservoir drill--in fluid provides the perfect solution for drilling and completion efficiency of a reservoir显示文摘 | Syed Ali Mark Luyster Arvind Patel | | SPE/IADC 1041100，，： | 1 |
| 9 | New opportunities for the drilling industry through innovative emulsifier chemistry显示文摘 | Arvind Patel Syed All | | SPE0，，： | 1 |
| 10 | Novel lipid based oral formulation of curcumin: Development and optimization by design of experiments approach显示文摘 | Yogesh B. Pawar Hitesh Purohit Guru Raghavendra Valicherla Bhushan Munjal Shantanu V. Lale Sarsvatkumar B. Patel Arvind Kumar Bansal | 2012 | International Journal of Pharmaceutics (-)2012，，1： | 1 |
| 11 | Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice显示文摘 | Krzysztof Lacek Koen Vercauteren Katarzyna Grzyb Mariarosaria Naddeo Lieven Verhoye Marek Patryk S?owikowski Samira Fafi-Kremer Arvind H. Patel Thomas F. Baumert Antonella Folgori Geert Leroux-Roels Riccardo Cortese Philip Meuleman Alfredo Nicosia | 2012 | Journal of Hepatology2012，，1： | 1 |
| 12 | Simultaneous analysis of allopurinol and oxypurinol using a validated liquid chromatography–tandem mass spectrometry method in human plasma显示文摘The present study describes a simple, reliable and reproducible liquid chromatography–tandem mass spectrometry method(LC–MS/MS) for the simultaneous determination of allopurinol and its active metabolite,oxypurinol in human plasma for a pharmacokinetic/bioequivalence study. After protein precipitation(PPT) of100 μL plasma sample with 1.0% formic acid in acetonitrile, the recovery of the analytes and allopurinol-d2 as an internal standard ranged from 85.36% to 91.20%. The analytes were separated on Hypersil Gold(150 mm×4.6 mm, 5 μm) column using 0.1% formic acid-acetonitrile(98:2, v/v) as the mobile phase.Quantification was done using electrospray ionization in the positive mode. The calibration concentration range was established from 60.0 to 6000 ng/m L for allopurinol and 80.0–8000 ng/m L for oxypurinol. Matrix effect in human plasma, expressed as IS-normalized matrix factors ranged from 1.003 to 1.030 for both the analytes. The developed method was found suitable for a clinical study with 300 mg allopurinol tablet formulation in healthy subjects. | Dhiraj M. Rathod Keyur R. Patel Hiren N. Mistri Arvind G. Jangid Pranav S. Shrivastav Mallika Sanyal | 2017 | Journal of Pharmaceutical Analysis2017，7，1： | 0 |
| 13 | Safety and performance of the EverProTM everolimus-eluting coronary stent system with biodegradable polymer in a real-world scenario显示文摘BACKGROUND The EverProTM(Sahajanand Laser Technology Ltd.,India)everolimus-eluting coronary stent system(EES)is a second-generation drug-eluting stent with a biodegradable polymer.AIM To determine the safety and performance of the EverProTM EES in patients with coronary artery disease(CAD)during a 1-year clinical follow-up.METHODS This observational,retrospective,single-center study enrolled patients who had been implanted with the EverProTM stent between June 1,2018 and January 31,2019,and had completed a 1-year follow-up period after the index procedure.The primary clinical endpoint was major adverse cardiac events(MACE)at 6 mo defined as the composite of cardiac death,myocardial infarction(MI),and target lesion revascularization(TLR).Secondary endpoints were the incidence of TLR at 1,6 and 12 mo follow-up,MACE at 1 and 12 mo follow-up,and stent thrombosis up to 1 year after the index procedure.RESULTS The study population comprised 77 patients(98 lesions).A total of 37(48.1%)patients had comorbid hypertension.In total,26(33.8%)patients presented with ST segment elevation MI and 10.4%patients with non-ST segment elevation MI.Treated lesions were located mainly in the left anterior descending artery(49%)followed by the right coronary artery(29.6%),left circumflex(12.2%)and obtuse marginal(9.2%)arteries.The majority of patients were with single-vessel disease(79%),22.2%of lesions had a mild to severe thrombus load,and 94.9%were American College of Cardiology/American Heart Association type B or C.De novo stenting was performed in 96.9%of patients and 3%were treated for in-stent restenosis.Procedural success was attained in all patients.In-hospital or followup MACE and stent thrombosis were not reported during the 1-year follow-up period.CONCLUSION These findings suggest that the EverProTM EES is a safe and effective treatment option with no MACE or stent thrombosis reported during the 1-year study period in patients with CAD. | Rahul Trimukhe Preeti Vani Arvind Patel Vikas Salgotra | 2020 | World Journal of Cardiology2020，12，12： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员